Platinum-based chemotherapy in triple negative breast cancer;Platin-basierte Therapie beim dreifach negativen Mammakarzinom

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 7, 2012, Pages 333-336

  Eckstein, N ^a   Haas, B ^a  

^a Bundesinstitut für Arzneimittel und Medizinprodukte ^*  (Germany)

Author keywords

carboplatin; cisplatin; triple negative breast cancer

Indexed keywords

PLATINUM COMPLEX;

BREAST CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PLATINUM;

EID: 84857005321     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1298891     Document Type: Review

References (12)

1. Rosenberg B, Vancamp L, Krigas T. Inhibiton of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature: 1965; 205 698 699
2. Stemmler HJ, DiGioia D, Freier W et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer: 2011; 104 1071 1078
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery: 2005; 4 307 320 (Pubitemid 41130944)
4. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol: 2007; 63 12 31 (Pubitemid 46810280)
5. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin: 2011; 61 212 236
6. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer: 2004; 11 497 522 (Pubitemid 39331280)
7. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell: 2006; 10 515 527 (Pubitemid 44854747)
8. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med: 2011; 364 205 214
9. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res: 2010; 70 7970 7980
10. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res: 2007; 13 2329 2334 (Pubitemid 46698581)
11. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A: 2003; 100 8418 8423 (Pubitemid 36842560)
12. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet: 2004; 41 1 5 (Pubitemid 38125677)